Mark Erlander insider trades: Cardiff Oncology (CRDF) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mark reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 25, 2022 | CRDF | ↑ Buy | 10,000 | $1.43 | $14K | Direct | Nov 29, 2022 (4d) |
| Mar 23, 2021 | CRDF | ↑ Buy | 965 | $10.34 | $10K | Direct | Mar 23, 2021 (0d) |
| May 14, 2020 | CRDF | ↑ Buy | 6,993 | $1.43 | $10K | Direct | May 18, 2020 (4d) |
| Dec 14, 2016 | TROV | ↑ Buy | 5,000 | $2.08 | $10K | Direct | Dec 15, 2016 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CRDF insiders
Open-market trades in the last 12 months
About Mark Erlander's insider trades
Mark Erlander is Chief Executive Officer at Cardiff Oncology (CRDF). Since Dec 14, 2016, Mark has reported 4 open-market purchases worth $45K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (14 filings), shares withheld for taxes (13 filings), option exercises (13 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CRDF insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.